Orforglipron(CAS:2212020-52-3)

Orforglipron, CAS number 2212020-52-3, is the world’s first oral small-molecule GLP-1 receptor agonist originally discovered by Chugai Pharmaceutical and exclusively commercialized by Eli Lilly, officially FDA-approved in April 2026. It fundamentally breaks the industrial bottleneck that peptide GLP-1 agents require injection and strict fasting, holding exclusive differentiated advantages in the treatment of obesity and type 2 diabetes. It is widely applied across the whole industrial chain including new drug application, generic mass production and metabolic pharmacological research. Its calcium salt form is white to pale brown solid with stable chemical structure and strong resistance to gastrointestinal degradation. Strict control over chiral impurities, related substances, heavy metals and residual solvents fully complies with USP and EP pharmacopoeia standards. Favorable water solubility supports mass manufacturing of oral film-coated tablets with uniform batch quality, covering all purchasing demands from lab-scale research, pilot amplification to large-scale preparation export.

In terms of core pharmacological mechanism, Orforglipron owns two innovative advantages distinct from peptide GLP-1s. Firstly, it adopts small-molecule allosteric binding mode: instead of binding the extracellular peptide pocket, it targets the transmembrane allosteric site to activate GLP-1 receptor. Its low molecular weight brings strong gastric acid resistance and high intestinal absorption efficiency without penetration enhancers. Secondly, it features Gs-biased agonism: after administration, it preferentially activates the adenylyl cyclase-cAMP-PKA hypoglycemic pathway with minimal β-arrestin recruitment, drastically reducing efficacy attenuation caused by receptor internalization and desensitization to maintain stable long-term therapeutic response. Multiple synergistic pathways regulate metabolism: it acts on central hypothalamic appetite center to lower hunger signal secretion and cut daily calorie intake; delays gastric emptying in gastrointestinal tract to enhance satiety; targets pancreatic β-cells to trigger glucose-dependent insulin secretion without hypoglycemia risk under low blood glucose; meanwhile suppresses excessive glucagon release to stabilize fasting and postprandial blood glucose. Long-term administration preferentially reduces visceral fat mass and improves cardiovascular risk markers including blood pressure and blood lipids, delivering triple target-organ protection of weight loss, glycemic control and vascular protection.

Clinically, Orforglipron owns two core approved indications. The first is long-term weight management for obese or overweight adults complicated with at least one metabolic comorbidity such as hypertension, dyslipidemia and type 2 diabetes. Phase 3 ATTAIN trial data showed the highest dose group achieved average 12.4% body weight reduction over 72 weeks, and nearly 40% participants lost more than 15% of baseline weight with far superior fat-losing efficacy versus placebo. The second indication is glycemic control for type 2 diabetes. ACHIEVE trial series verified monotherapy reduces HbA1c by 1.3% to 1.6% and stabilizes all-day glucose fluctuation. Its biggest clinical highlight is unrestricted administration: it can be taken at any time of day with or without meals, no large water intake required, remarkably improving long-term medication adherence. It can be used as monotherapy or combined with metformin and SGLT2 inhibitors for synergistic efficacy. Extended clinical trials are ongoing for obstructive sleep apnea and metabolic hypertension to continuously expand applicable scenarios.

Regarding industrial production and clinical safety, Orforglipron adopts patent-optimized total synthesis and purification technology with precisely controlled impurity limits and stable mass production costs, enabling continuous bulk supply for pharmaceutical manufacturers. Its overall tolerance is comparable to injectable GLP-1 agents, with mild to moderate gastrointestinal adverse reactions that gradually relieve with prolonged treatment. No definite liver injury safety signal or severe hypoglycemia risk is observed, presenting a wide therapeutic safety window. As a landmark oral GLP-1 API in metabolic drug development over the past decade, Orforglipron addresses pain points of traditional peptide preparations including injection discomfort, strict administration restrictions and poor adherence. With continuously rising global prevalence of obesity and diabetes, it holds irreplaceable market competitiveness in high-end oral metabolic generics, innovative weight-loss and hypoglycemic formulations and export API supply, promising broad and sustainable long-term development prospects across the global pharmaceutical industry.